Emergent BioSolutions Inc. - 8-K Filing
Emergent BioSolutions secured a $52.7 million contract modification from the U.S. government to supply ACAM2000® (Smallpox and Mpox Vaccine) under its existing 10-year agreement with ASPR, effective June 26, 2026. Deliveries of doses, ancillaries, and diluent replacement lots are expected in June and December 2026. (Items: 1.01 Entry into a Material Definitive AgreementOn June 26, 2026 , Emergent BioSolutions Inc, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $EBS